id,payer_region,therapy_area,compound,indication,comparator_context,value_manifold_snapshot,payer_stress_summary,design_constraints,RWE_feasibility_notes,pricing_constraints,optimal_endpoint_mix,RWE_generation_plan,pricing_stability_zone,access_probability,restriction_burden_forecast,coverage_stability_horizon,confidence_score,notes,constraints,gold_checklist
RPOF-001,"EU HTA","oncology","drug-A","metastatic tumor","SOC chemo","benefit high; cost high; evidence mid","ICER pressure; long-term OS gap","limited sample; OS follow-up possible","registry linkage available","price flexibility limited","OS + QoL + TTD","EU registry linkage; post-launch OS follow-up; subgroup persistence","narrow","0.58","moderate restrictions","2y","0.74","needs durability proof","Under 280 words","endpoints+rwe+price+access+restrict+horizon+confidence"
RPOF-002,"UK payer","autoimmune","drug-B","RA","TNF inhibitors","benefit mid; cost mid; evidence mid","head-to-head missing; comparator risk","add head-to-head feasible","NHS EHR strong","price flexible","head-to-head ACR + flare rate + steroid-sparing","NHS comparative RWE; persistence; discontinuation reasons","moderate","0.62","step therapy likely","3y","0.72","solve comparator","Under 280 words","endpoints+rwe+price+access+restrict+horizon+confidence"
RPOF-003,"US commercial","rare disease","drug-C","enzyme deficiency","none","benefit high; cost very high; evidence low","budget impact; small n","single-arm only","registry feasible","price inflexible","functional endpoint + hospitalization + caregiver burden","expand registry; natural history comparator; claims linkage","narrow","0.55","prior auth heavy","2y","0.73","orphan path","Under 280 words","endpoints+rwe+price+access+restrict+horizon+confidence"
RPOF-004,"EU HTA","cardio","drug-D","HFpEF","ACEi","benefit low-mid; cost low; evidence mid","endpoint fragility; heterogeneity","longer follow-up needed","claims + EHR feasible","price flexible","MACE + hospitalization + subgroup enrichment","RWE outcomes study; heterogeneity mapping; adherence analysis","wide","0.70","low restrictions","4y","0.70","cheap but modest","Under 280 words","endpoints+rwe+price+access+restrict+horizon+confidence"
RPOF-005,"US PBM","neuro","drug-E","migraine","CGRP class","benefit mid; cost high; evidence low-mid","class crowding; durability unknown","extension study feasible","claims feasible; PRO app feasible","price flexibility moderate","durability + responder rate + functional days","claims persistence; PRO burden reduction; discontinuation mapping","narrow","0.54","tiering + prior auth","18m","0.71","needs differentiation","Under 280 words","endpoints+rwe+price+access+restrict+horizon+confidence"
RPOF-006,"EU HTA","metabolic","drug-F","T2D","GLP-1","benefit low-mid; cost mid; evidence mid","outcomes missing; weak differentiation","CV outcomes feasible","EHR + registry feasible","price flexible","CV outcomes + weight + renal endpoints","RWE CV outcomes; adherence; renal subgroup durability","moderate","0.63","moderate restrictions","3y","0.69","outcomes proof","Under 280 words","endpoints+rwe+price+access+restrict+horizon+confidence"